[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHC19UTdGHUc5cjcYAxGah-d_Pf33q34l25HSdOttw1I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":8,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":78,"rows":85},"Swedish Orphan Biovitrum",[4],76,false,11,19,10490,6,[13,16,19,21,23,26,28,30],{"name":14,"count":15},"Hemophilia A",8,{"name":17,"count":18},"Still's Disease, Adult-Onset",4,{"name":20,"count":18},"Hereditary Tyrosinemia, Type I",{"name":22,"count":18},"Haemophilia B",{"name":24,"count":25},"Macrophage Activation Syndrome",3,{"name":27,"count":25},"Leukemia",{"name":29,"count":25},"Head and Neck Cancer",{"name":31,"count":25},"Healthy Volunteers",[33,38,43,47,52,57,62,66,70,74],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05814159","A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)","2025-12-10","Anakinra",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05817812","A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa","2026-05-22","Efanesoctocog alfa",{"nctId":44,"briefTitle":45,"date":46,"intervention":42},"NCT06579144","Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","2026-05-30",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04293523","A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health","2026-07","ELOCTA",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05776472","A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","2026-08-15","Pegcetacoplan",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03165734","A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","2026-10-05","Pacritinib",{"nctId":63,"briefTitle":64,"date":65,"intervention":42},"NCT06752850","A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis","2026-11-17",{"nctId":67,"briefTitle":68,"date":69,"intervention":61},"NCT06782373","A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","2026-12-30",{"nctId":71,"briefTitle":72,"date":73,"intervention":42},"NCT06716814","Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","2027-03",{"nctId":75,"briefTitle":76,"date":77,"intervention":37},"NCT06666335","A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF","2027-08-30",[79,80,81,82,83,84],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[86,148,234,268,286,327,358,385,409,434,554,629,682,725,762,784,802,820,846,864,888,906,939,966,984,1002,1020,1038,1056,1080,1110,1132,1157,1175,1193,1211,1235,1258,1276,1294,1325,1343,1361,1379,1397,1415,1439,1457,1505,1542,1566,1584],{"intervention":42,"totalTrials":87,"cells":88},5,{"EARLY_PHASE1":89,"PHASE1":92,"PHASE2":102,"PHASE3":104,"PHASE4":123,"NA":146},{"trials":90,"activeCount":91},[],0,{"trials":93,"activeCount":101,"soonestReadout":46},[94],{"nctId":44,"briefTitle":45,"status":95,"phases":96,"primaryCompletion":46,"completion":46,"start":97,"enrollment":98,"conditions":99,"interventions":100},"RECRUITING",[80],"2025-02-24",24,[14],[42],1,{"trials":103,"activeCount":91},[],{"trials":105,"activeCount":122,"soonestReadout":41},[106,115],{"nctId":39,"briefTitle":40,"status":107,"phases":108,"primaryCompletion":41,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"ACTIVE_NOT_RECRUITING",[82],"2026-06-12","2023-07-31",93,[113],"Hemophilia A, Severe",[42],{"nctId":71,"briefTitle":72,"status":95,"phases":116,"primaryCompletion":73,"completion":73,"start":117,"enrollment":118,"conditions":119,"interventions":121},[82],"2025-03-06",104,[120],"Haemophilia A (Moderate or Severe)",[42],2,{"trials":124,"activeCount":122,"soonestReadout":65},[125,134],{"nctId":126,"briefTitle":127,"status":95,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NCT06940830","Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa",[83],"2028-12","2025-05-21",250,[14],[42],{"nctId":63,"briefTitle":64,"status":107,"phases":135,"primaryCompletion":65,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":145},[83],"2026-12-28","2024-12-19",37,[120,140,141,142,143,144],"Hemophilia, Classic","Haemophilia","Hemophilia","Classic Hemophilia","Synovial Hypertrophy",[42],{"trials":147,"activeCount":91},[],{"intervention":37,"totalTrials":149,"cells":150},7,{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":191,"NA":201},{"trials":152,"activeCount":91},[],{"trials":154,"activeCount":91},[],{"trials":156,"activeCount":91},[],{"trials":158,"activeCount":101,"soonestReadout":36},[159,172,180],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT03265132","A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)","TERMINATED",[82],"2019-02-13","2019-05-23","2017-09-26",13,[17,169],"Still's Disease, Juvenile-Onset",[171],"anakinra",{"nctId":34,"briefTitle":35,"status":107,"phases":173,"primaryCompletion":36,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},[82],"2026-06-24","2022-08-24",15,[178,17],"Still's Disease, Juvenile Onset",[37],{"nctId":181,"briefTitle":182,"status":162,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT04324021","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.",[81,82],"2020-11-13","2020-04-02",16,[188],"SARS-CoV-2",[190,37],"Emapalumab",{"trials":192,"activeCount":101,"soonestReadout":77},[193],{"nctId":75,"briefTitle":76,"status":194,"phases":195,"primaryCompletion":77,"completion":196,"start":197,"enrollment":25,"conditions":198,"interventions":200},"NOT_YET_RECRUITING",[83],"2027-11-30","2025-09-01",[199],"Familial Mediterranean Fever (FMF )",[37],{"trials":202,"activeCount":91},[203,214,224],{"nctId":204,"briefTitle":205,"status":206,"phases":207,"primaryCompletion":208,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT02326376","Kineret CAPS Post Authorisation Study","COMPLETED",[],"2019-09-12","2015-04-24",12,[212],"Cryopyrin-Associated Periodic Syndromes",[171],{"nctId":215,"briefTitle":216,"status":206,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT03932344","Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)",[],"2019-08-31","2019-04-10",306,[222],"Still Disease, Juvenile Onset",[37],{"nctId":225,"briefTitle":226,"status":206,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT02915094","Kineret in the Treatment of Rheumatoid Arthritis",[],"2016-01","2012-10",30,[232],"Rheumatoid Arthritis",[37],{"intervention":61,"totalTrials":122,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":251,"PHASE4":264,"NA":266},{"trials":237,"activeCount":91},[],{"trials":239,"activeCount":91},[],{"trials":241,"activeCount":101,"soonestReadout":69},[242],{"nctId":67,"briefTitle":68,"status":95,"phases":243,"primaryCompletion":69,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":250},[81],"2028-05-22","2025-05-28",78,[248,249],"VEXAS","VEXAS Syndrome",[61],{"trials":252,"activeCount":101,"soonestReadout":60},[253],{"nctId":58,"briefTitle":59,"status":107,"phases":254,"primaryCompletion":60,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":262},[82],"2028-10-13","2017-06-26",407,[259,260,261],"Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[61,263],"Physician's Choice medications",{"trials":265,"activeCount":91},[],{"trials":267,"activeCount":91},[],{"intervention":263,"totalTrials":101,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":282,"NA":284},{"trials":271,"activeCount":91},[],{"trials":273,"activeCount":91},[],{"trials":275,"activeCount":91},[],{"trials":277,"activeCount":101,"soonestReadout":60},[278],{"nctId":58,"briefTitle":59,"status":107,"phases":279,"primaryCompletion":60,"completion":255,"start":256,"enrollment":257,"conditions":280,"interventions":281},[82],[259,260,261],[61,263],{"trials":283,"activeCount":91},[],{"trials":285,"activeCount":91},[],{"intervention":56,"totalTrials":25,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":303,"PHASE4":315,"NA":317},{"trials":289,"activeCount":91},[],{"trials":291,"activeCount":91},[],{"trials":293,"activeCount":91},[294],{"nctId":295,"briefTitle":296,"status":206,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":210,"conditions":300,"interventions":302},"NCT05148299","A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation",[81],"2024-12-08","2022-02-01",[301],"Transplant-Associated Thrombotic Microangiopathy",[56],{"trials":304,"activeCount":91},[305],{"nctId":306,"briefTitle":307,"status":206,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":98,"conditions":312,"interventions":314},"NCT05096403","A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)",[82],"2024-05-27","2024-09-11","2022-10-20",[313],"Cold Agglutinin Disease",[56],{"trials":316,"activeCount":91},[],{"trials":318,"activeCount":101,"soonestReadout":55},[319],{"nctId":53,"briefTitle":54,"status":95,"phases":320,"primaryCompletion":55,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},[],"2029-08-15","2023-06-26",200,[325],"Paroxysmal Nocturnal Hemoglobinuria",[56],{"intervention":51,"totalTrials":122,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":330,"activeCount":91},[],{"trials":332,"activeCount":91},[],{"trials":334,"activeCount":91},[],{"trials":336,"activeCount":91},[],{"trials":338,"activeCount":91},[],{"trials":340,"activeCount":101,"soonestReadout":50},[341,347],{"nctId":48,"briefTitle":49,"status":107,"phases":342,"primaryCompletion":50,"completion":50,"start":343,"enrollment":344,"conditions":345,"interventions":346},[],"2020-03-30",427,[14],[51],{"nctId":348,"briefTitle":349,"status":206,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT03055611","A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B",[],"2022-04-19","2017-05-09",201,[355,22],"Haemophilia A",[51,357],"ALPROLIX",{"intervention":359,"totalTrials":101,"cells":360},"Kepivance",{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":383},{"trials":362,"activeCount":91},[],{"trials":364,"activeCount":91},[],{"trials":366,"activeCount":91},[],{"trials":368,"activeCount":91},[],{"trials":370,"activeCount":91},[371],{"nctId":372,"briefTitle":373,"status":206,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":382},"NCT00352703","PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation",[83],"2007-04","2007-05","2006-04",145,[380,381],"Non-Hodgkin's Lymphoma","Multiple Myeloma",[359],{"trials":384,"activeCount":91},[],{"intervention":386,"totalTrials":101,"cells":387},"Recombinant coagulation factor",{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":407},{"trials":389,"activeCount":91},[],{"trials":391,"activeCount":91},[],{"trials":393,"activeCount":91},[],{"trials":395,"activeCount":91},[],{"trials":397,"activeCount":91},[398],{"nctId":399,"briefTitle":400,"status":206,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":186,"conditions":405,"interventions":406},"NCT03103542","Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies",[83],"2019-09-04","2020-08-31","2017-08-29",[14],[386],{"trials":408,"activeCount":91},[],{"intervention":410,"totalTrials":101,"cells":411},"Emapalumab-Lzsg 5 MG\u002FML [Gamifant]",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":432},{"trials":413,"activeCount":91},[],{"trials":415,"activeCount":91},[],{"trials":417,"activeCount":91},[],{"trials":419,"activeCount":91},[],{"trials":421,"activeCount":91},[422],{"nctId":423,"briefTitle":424,"status":206,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":167,"conditions":429,"interventions":431},"NCT05744063","A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients",[83],"2025-02-21","2025-08-08","2023-02-03",[430],"Primary Hemophagocytic Lymphohistiocytosis",[410],{"trials":433,"activeCount":91},[],{"intervention":435,"totalTrials":436,"cells":437},"Palifermin",9,{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":472,"PHASE3":521,"PHASE4":550,"NA":552},{"trials":439,"activeCount":91},[],{"trials":441,"activeCount":91},[442,452,463],{"nctId":443,"briefTitle":444,"status":206,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT00460421","A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT",[80],"2011-05","2006-08",27,[27],[435,451],"Chemotherapy",{"nctId":453,"briefTitle":454,"status":206,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT01163097","Study to Characterize the Effect of Heparin on Palifermin Activity",[80],"2011-01","2010-07",44,[460],"Oral Mucositis",[435,462],"Heparin",{"nctId":464,"briefTitle":465,"status":206,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT00361348","Palifermin DDI (Drug Drug Interaction)",[80],"2006-07","2005-12",45,[31],[435,462],{"trials":473,"activeCount":91},[474,489,499,509],{"nctId":475,"briefTitle":476,"status":206,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":486},"NCT00094861","Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",[81],"2007-12","2014-01","2005-01",100,[483,484,485],"Dysphagia","Non-Small Cell Lung Cancer","Lung Cancer",[435,487,488],"Paclitaxel","Carboplatin",{"nctId":490,"briefTitle":491,"status":492,"phases":493,"primaryCompletion":494,"completion":494,"start":495,"enrollment":91,"conditions":496,"interventions":497},"NCT00540332","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy","WITHDRAWN",[80,81],"2008-09","2007-10",[29],[498],"palifermin",{"nctId":500,"briefTitle":501,"status":206,"phases":502,"primaryCompletion":376,"completion":503,"start":504,"enrollment":87,"conditions":505,"interventions":507},"NCT00626639","A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy",[80,81],"2015-07","2005-07",[506,29],"Mucositis",[498,508],"Cisplatin",{"nctId":510,"briefTitle":511,"status":206,"phases":512,"primaryCompletion":513,"completion":514,"start":468,"enrollment":515,"conditions":516,"interventions":519},"NCT00189488","Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow\u002FPeripheral Blood Progenitor Cell (PBPC) Transplantation",[81],"2008-11","2013-08",155,[517,518],"Graft Versus Host Disease","Hematologic Malignancies",[435,520],"Methotrexate",{"trials":522,"activeCount":91},[523,536],{"nctId":524,"briefTitle":525,"status":206,"phases":526,"primaryCompletion":527,"completion":528,"start":480,"enrollment":529,"conditions":530,"interventions":533},"NCT00109031","Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)",[82],"2006-02","2010-12",47,[531,532,27],"Cancer","Lymphoma",[498,534,535],"Cyclophosphamide","Etoposide",{"nctId":537,"briefTitle":538,"status":206,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":548},"NCT00101582","Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer",[82],"2007-09","2016-08","2005-08",188,[506,545,546,29,547],"Solid Tumors","Stomatitis","Squamous Cell Carcinoma",[498,549],"cisplatin chemotherapy",{"trials":551,"activeCount":91},[],{"trials":553,"activeCount":91},[],{"intervention":190,"totalTrials":11,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":583,"PHASE4":625,"NA":627},{"trials":557,"activeCount":91},[],{"trials":559,"activeCount":91},[],{"trials":561,"activeCount":91},[562,571],{"nctId":563,"briefTitle":564,"status":162,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":122,"conditions":568,"interventions":570},"NCT04731298","Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.",[81],"2022-04-21","2021-05-25",[569],"Graft Failure",[190],{"nctId":572,"briefTitle":573,"status":206,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":582},"NCT03311854","A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome\u002FSecondary HLH (MAS\u002FsHLH)",[81],"2020-05-19","2018-02-20",14,[24,579,580,581],"Lymphohistiocytosis, Hemophagocytic","Arthritis, Juvenile","Adult Onset Still Disease",[190],{"trials":584,"activeCount":91},[585,601,611,621],{"nctId":586,"briefTitle":587,"status":206,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":600},"NCT05001737","Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE",[82],"2024-06-30","2025-06-04","2021-12-15",33,[24,594,595,596,597,598,599],"Secondary Hemophagocytic Lymphohistiocytosis","Still Disease","Systemic Lupus Erythematosus","SJIA","AOSD","MAS",[190],{"nctId":602,"briefTitle":603,"status":206,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":610},"NCT02069899","A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody",[81,82],"2021-05-18","2014-08-04",58,[609],"Hemophagocytic Lymphohistiocytosis",[190],{"nctId":612,"briefTitle":613,"status":206,"phases":614,"primaryCompletion":615,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":620},"NCT03312751","Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis",[82],"2021-08-18","2022-09-14","2019-02-06",35,[430],[190],{"nctId":181,"briefTitle":182,"status":162,"phases":622,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":623,"interventions":624},[81,82],[188],[190,37],{"trials":626,"activeCount":91},[],{"trials":628,"activeCount":91},[],{"intervention":630,"totalTrials":18,"cells":631},"rhBSSL",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":666,"PHASE4":678,"NA":680},{"trials":633,"activeCount":91},[],{"trials":635,"activeCount":91},[],{"trials":637,"activeCount":91},[638,648,658],{"nctId":639,"briefTitle":640,"status":206,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":176,"conditions":644,"interventions":647},"NCT00743483","Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency",[81],"2009-06","2008-08",[645,646],"Cystic Fibrosis","Exocrine Pancreatic Insufficiency",[630],{"nctId":649,"briefTitle":650,"status":206,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT00659243","Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants",[81],"2010-02","2008-03",32,[656],"Replacement Therapy in Preterm Infants",[630],{"nctId":659,"briefTitle":660,"status":206,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":592,"conditions":664,"interventions":665},"NCT00658905","Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants",[81],"2009-05","2008-04",[656],[630],{"trials":667,"activeCount":91},[668],{"nctId":669,"briefTitle":670,"status":162,"phases":671,"primaryCompletion":672,"completion":673,"start":446,"enrollment":674,"conditions":675,"interventions":677},"NCT01413581","Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants",[82],"2013-07","2014-08",415,[676],"Prevention of Growth Restriction",[630],{"trials":679,"activeCount":91},[],{"trials":681,"activeCount":91},[],{"intervention":683,"totalTrials":25,"cells":684},"NI-0501",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":709,"PHASE3":711,"PHASE4":721,"NA":723},{"trials":686,"activeCount":91},[],{"trials":688,"activeCount":91},[689,698],{"nctId":690,"briefTitle":691,"status":206,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":697},"NCT01459562","First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers",[80],"2013-01","2011-09",20,[31],[683],{"nctId":699,"briefTitle":700,"status":206,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":15,"conditions":705,"interventions":707},"NCT04765553","A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.",[80],"2021-06-25","2021-07-25","2021-01-14",[706],"Rare Diseases",[683,708],"Saline",{"trials":710,"activeCount":91},[],{"trials":712,"activeCount":91},[713],{"nctId":714,"briefTitle":715,"status":206,"phases":716,"primaryCompletion":717,"completion":717,"start":672,"enrollment":469,"conditions":718,"interventions":720},"NCT01818492","Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis",[81,82],"2019-01",[719],"Primary Haemophagocytic Lymphohistiocytosis",[683],{"trials":722,"activeCount":91},[],{"trials":724,"activeCount":91},[],{"intervention":726,"totalTrials":122,"cells":727},"SEL-212 low-dose",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":758,"NA":760},{"trials":729,"activeCount":91},[],{"trials":731,"activeCount":91},[],{"trials":733,"activeCount":91},[],{"trials":735,"activeCount":91},[736,748],{"nctId":737,"briefTitle":738,"status":206,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT04513366","A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy",[82],"2022-07-21","2022-12-01","2020-08-18",112,[745],"Chronic Gout",[726,747],"SEL-212 high-dose",{"nctId":749,"briefTitle":750,"status":206,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT04596540","A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II",[82],"2023-01-10","2023-01-12","2020-11-30",153,[745],[726,747],{"trials":759,"activeCount":91},[],{"trials":761,"activeCount":91},[],{"intervention":747,"totalTrials":122,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":780,"NA":782},{"trials":765,"activeCount":91},[],{"trials":767,"activeCount":91},[],{"trials":769,"activeCount":91},[],{"trials":771,"activeCount":91},[772,776],{"nctId":737,"briefTitle":738,"status":206,"phases":773,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":774,"interventions":775},[82],[745],[726,747],{"nctId":749,"briefTitle":750,"status":206,"phases":777,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":778,"interventions":779},[82],[745],[726,747],{"trials":781,"activeCount":91},[],{"trials":783,"activeCount":91},[],{"intervention":534,"totalTrials":101,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":798,"NA":800},{"trials":787,"activeCount":91},[],{"trials":789,"activeCount":91},[],{"trials":791,"activeCount":91},[],{"trials":793,"activeCount":91},[794],{"nctId":524,"briefTitle":525,"status":206,"phases":795,"primaryCompletion":527,"completion":528,"start":480,"enrollment":529,"conditions":796,"interventions":797},[82],[531,532,27],[498,534,535],{"trials":799,"activeCount":91},[],{"trials":801,"activeCount":91},[],{"intervention":535,"totalTrials":101,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":816,"NA":818},{"trials":805,"activeCount":91},[],{"trials":807,"activeCount":91},[],{"trials":809,"activeCount":91},[],{"trials":811,"activeCount":91},[812],{"nctId":524,"briefTitle":525,"status":206,"phases":813,"primaryCompletion":527,"completion":528,"start":480,"enrollment":529,"conditions":814,"interventions":815},[82],[531,532,27],[498,534,535],{"trials":817,"activeCount":91},[],{"trials":819,"activeCount":91},[],{"intervention":821,"totalTrials":101,"cells":822},"Palifermin before only",{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":842,"NA":844},{"trials":824,"activeCount":91},[],{"trials":826,"activeCount":91},[],{"trials":828,"activeCount":91},[],{"trials":830,"activeCount":91},[831],{"nctId":832,"briefTitle":833,"status":206,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":840},"NCT00434161","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma",[82],"2009-03","2012-05","2006-12",281,[381],[821,841],"Palifermin before and after",{"trials":843,"activeCount":91},[],{"trials":845,"activeCount":91},[],{"intervention":841,"totalTrials":101,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":860,"NA":862},{"trials":849,"activeCount":91},[],{"trials":851,"activeCount":91},[],{"trials":853,"activeCount":91},[],{"trials":855,"activeCount":91},[856],{"nctId":832,"briefTitle":833,"status":206,"phases":857,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":858,"interventions":859},[82],[381],[821,841],{"trials":861,"activeCount":91},[],{"trials":863,"activeCount":91},[],{"intervention":865,"totalTrials":101,"cells":866},"Emapalumab-Lzsg",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":884,"NA":886},{"trials":868,"activeCount":91},[],{"trials":870,"activeCount":91},[],{"trials":872,"activeCount":91},[],{"trials":874,"activeCount":91},[875],{"nctId":876,"briefTitle":877,"status":162,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":149,"conditions":881,"interventions":883},"NCT03985423","A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH",[81,82],"2021-06-29","2020-06-02",[882],"Hemophagocytic Lymphohistiocytoses",[865],{"trials":885,"activeCount":91},[],{"trials":887,"activeCount":91},[],{"intervention":549,"totalTrials":101,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":902,"NA":904},{"trials":891,"activeCount":91},[],{"trials":893,"activeCount":91},[],{"trials":895,"activeCount":91},[],{"trials":897,"activeCount":91},[898],{"nctId":537,"briefTitle":538,"status":206,"phases":899,"primaryCompletion":540,"completion":541,"start":542,"enrollment":543,"conditions":900,"interventions":901},[82],[506,545,546,29,547],[498,549],{"trials":903,"activeCount":91},[],{"trials":905,"activeCount":91},[],{"intervention":907,"totalTrials":122,"cells":908},"SOBI003",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":910,"activeCount":91},[],{"trials":912,"activeCount":91},[],{"trials":914,"activeCount":91},[915,925],{"nctId":916,"briefTitle":917,"status":206,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":11,"conditions":922,"interventions":924},"NCT03811028","A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients",[80,81],"2021-04-30","2021-05-07","2019-01-19",[923],"Sanfilippo Syndrome Type A (MPS IIIA)",[907],{"nctId":926,"briefTitle":927,"status":206,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":11,"conditions":931,"interventions":932},"NCT03423186","A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients",[80,81],"2019-10-25","2018-06-19",[923],[907],{"trials":934,"activeCount":91},[],{"trials":936,"activeCount":91},[],{"trials":938,"activeCount":91},[],{"intervention":940,"totalTrials":101,"cells":941},"Anakinra 100 mg",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":943,"activeCount":91},[],{"trials":945,"activeCount":91},[],{"trials":947,"activeCount":91},[948],{"nctId":949,"briefTitle":950,"status":206,"phases":951,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT03002974","A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis",[81],"2018-06","2019-08","2016-12",165,[957],"Acute Gouty Arthritis",[940,959],"Triamcinolone Acetonide 40 mg",{"trials":961,"activeCount":91},[],{"trials":963,"activeCount":91},[],{"trials":965,"activeCount":91},[],{"intervention":959,"totalTrials":101,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":969,"activeCount":91},[],{"trials":971,"activeCount":91},[],{"trials":973,"activeCount":91},[974],{"nctId":949,"briefTitle":950,"status":206,"phases":975,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":976,"interventions":977},[81],[957],[940,959],{"trials":979,"activeCount":91},[],{"trials":981,"activeCount":91},[],{"trials":983,"activeCount":91},[],{"intervention":487,"totalTrials":101,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":996,"PHASE4":998,"NA":1000},{"trials":987,"activeCount":91},[],{"trials":989,"activeCount":91},[],{"trials":991,"activeCount":91},[992],{"nctId":475,"briefTitle":476,"status":206,"phases":993,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":994,"interventions":995},[81],[483,484,485],[435,487,488],{"trials":997,"activeCount":91},[],{"trials":999,"activeCount":91},[],{"trials":1001,"activeCount":91},[],{"intervention":488,"totalTrials":101,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1014,"PHASE4":1016,"NA":1018},{"trials":1005,"activeCount":91},[],{"trials":1007,"activeCount":91},[],{"trials":1009,"activeCount":91},[1010],{"nctId":475,"briefTitle":476,"status":206,"phases":1011,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":1012,"interventions":1013},[81],[483,484,485],[435,487,488],{"trials":1015,"activeCount":91},[],{"trials":1017,"activeCount":91},[],{"trials":1019,"activeCount":91},[],{"intervention":508,"totalTrials":101,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1023,"activeCount":91},[],{"trials":1025,"activeCount":91},[],{"trials":1027,"activeCount":91},[1028],{"nctId":500,"briefTitle":501,"status":206,"phases":1029,"primaryCompletion":376,"completion":503,"start":504,"enrollment":87,"conditions":1030,"interventions":1031},[80,81],[506,29],[498,508],{"trials":1033,"activeCount":91},[],{"trials":1035,"activeCount":91},[],{"trials":1037,"activeCount":91},[],{"intervention":520,"totalTrials":101,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1050,"PHASE4":1052,"NA":1054},{"trials":1041,"activeCount":91},[],{"trials":1043,"activeCount":91},[],{"trials":1045,"activeCount":91},[1046],{"nctId":510,"briefTitle":511,"status":206,"phases":1047,"primaryCompletion":513,"completion":514,"start":468,"enrollment":515,"conditions":1048,"interventions":1049},[81],[517,518],[435,520],{"trials":1051,"activeCount":91},[],{"trials":1053,"activeCount":91},[],{"trials":1055,"activeCount":91},[],{"intervention":1057,"totalTrials":101,"cells":1058},"BVT.115959",{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1060,"activeCount":91},[],{"trials":1062,"activeCount":91},[],{"trials":1064,"activeCount":91},[1065],{"nctId":1066,"briefTitle":1067,"status":206,"phases":1068,"primaryCompletion":478,"completion":1069,"start":376,"enrollment":1070,"conditions":1071,"interventions":1073},"NCT00452777","Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain",[81],"2008-01",193,[1072],"Diabetic Neuropathic Pain",[1057],{"trials":1075,"activeCount":91},[],{"trials":1077,"activeCount":91},[],{"trials":1079,"activeCount":91},[],{"intervention":451,"totalTrials":122,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1083,"activeCount":91},[],{"trials":1085,"activeCount":91},[1086,1098],{"nctId":1087,"briefTitle":1088,"status":206,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1095},"NCT00070616","Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support",[80],"2005-03","2001-12",25,[27,532,1094],"Myeloma",[1096,1097,451],"Palifermin 6 x 60 μg\u002Fkg\u002Fday","Palifermin 2 x 180 μg\u002Fkg\u002Fday",{"nctId":443,"briefTitle":444,"status":206,"phases":1099,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":1100,"interventions":1101},[80],[27],[435,451],{"trials":1103,"activeCount":91},[],{"trials":1105,"activeCount":91},[],{"trials":1107,"activeCount":91},[],{"trials":1109,"activeCount":91},[],{"intervention":462,"totalTrials":122,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1113,"activeCount":91},[],{"trials":1115,"activeCount":91},[1116,1120],{"nctId":453,"briefTitle":454,"status":206,"phases":1117,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":1118,"interventions":1119},[80],[460],[435,462],{"nctId":464,"briefTitle":465,"status":206,"phases":1121,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":1122,"interventions":1123},[80],[31],[435,462],{"trials":1125,"activeCount":91},[],{"trials":1127,"activeCount":91},[],{"trials":1129,"activeCount":91},[],{"trials":1131,"activeCount":91},[],{"intervention":1133,"totalTrials":101,"cells":1134},"Nitisinone 20 mg",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1136,"activeCount":91},[],{"trials":1138,"activeCount":91},[1139],{"nctId":1140,"briefTitle":1141,"status":206,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":210,"conditions":1145,"interventions":1147},"NCT01857362","Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.",[80],"2013-06","2013-05",[1146],"Healthy",[1133,1148],"Nitisinone 10 mg",{"trials":1150,"activeCount":91},[],{"trials":1152,"activeCount":91},[],{"trials":1154,"activeCount":91},[],{"trials":1156,"activeCount":91},[],{"intervention":1148,"totalTrials":101,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":91},[],{"trials":1162,"activeCount":91},[1163],{"nctId":1140,"briefTitle":1141,"status":206,"phases":1164,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":210,"conditions":1165,"interventions":1166},[80],[1146],[1133,1148],{"trials":1168,"activeCount":91},[],{"trials":1170,"activeCount":91},[],{"trials":1172,"activeCount":91},[],{"trials":1174,"activeCount":91},[],{"intervention":1096,"totalTrials":101,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":91},[],{"trials":1180,"activeCount":91},[1181],{"nctId":1087,"briefTitle":1088,"status":206,"phases":1182,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":1183,"interventions":1184},[80],[27,532,1094],[1096,1097,451],{"trials":1186,"activeCount":91},[],{"trials":1188,"activeCount":91},[],{"trials":1190,"activeCount":91},[],{"trials":1192,"activeCount":91},[],{"intervention":1097,"totalTrials":101,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":91},[],{"trials":1198,"activeCount":91},[1199],{"nctId":1087,"briefTitle":1088,"status":206,"phases":1200,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":1201,"interventions":1202},[80],[27,532,1094],[1096,1097,451],{"trials":1204,"activeCount":91},[],{"trials":1206,"activeCount":91},[],{"trials":1208,"activeCount":91},[],{"trials":1210,"activeCount":91},[],{"intervention":1212,"totalTrials":101,"cells":1213},"SOBI002",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1227,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1215,"activeCount":91},[],{"trials":1217,"activeCount":91},[1218],{"nctId":1219,"briefTitle":1220,"status":162,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":98,"conditions":1225,"interventions":1226},"NCT02083666","Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration",[80],"2014-11","2015-02","2013-12",[1146],[1212],{"trials":1228,"activeCount":91},[],{"trials":1230,"activeCount":91},[],{"trials":1232,"activeCount":91},[],{"trials":1234,"activeCount":91},[],{"intervention":1236,"totalTrials":101,"cells":1237},"Nitisinone,",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1239,"activeCount":91},[],{"trials":1241,"activeCount":91},[1242],{"nctId":1243,"briefTitle":1244,"status":206,"phases":1245,"primaryCompletion":229,"completion":229,"start":1246,"enrollment":210,"conditions":1247,"interventions":1248},"NCT01682538","Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension",[80],"2012-08",[31],[1236,1249],"Nitisinone, suspension",{"trials":1251,"activeCount":91},[],{"trials":1253,"activeCount":91},[],{"trials":1255,"activeCount":91},[],{"trials":1257,"activeCount":91},[],{"intervention":1249,"totalTrials":101,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":91},[],{"trials":1263,"activeCount":91},[1264],{"nctId":1243,"briefTitle":1244,"status":206,"phases":1265,"primaryCompletion":229,"completion":229,"start":1246,"enrollment":210,"conditions":1266,"interventions":1267},[80],[31],[1236,1249],{"trials":1269,"activeCount":91},[],{"trials":1271,"activeCount":91},[],{"trials":1273,"activeCount":91},[],{"trials":1275,"activeCount":91},[],{"intervention":708,"totalTrials":101,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":91},[],{"trials":1281,"activeCount":91},[1282],{"nctId":699,"briefTitle":700,"status":206,"phases":1283,"primaryCompletion":702,"completion":703,"start":704,"enrollment":15,"conditions":1284,"interventions":1285},[80],[706],[683,708],{"trials":1287,"activeCount":91},[],{"trials":1289,"activeCount":91},[],{"trials":1291,"activeCount":91},[],{"trials":1293,"activeCount":91},[],{"intervention":1295,"totalTrials":101,"cells":1296},"Nitisinone in Arm A",{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1298,"activeCount":91},[],{"trials":1300,"activeCount":91},[1301],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1304,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1311},"NCT03103568","A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers",[80],"2017-06-10","2017-07-24","2017-03-28",36,[1310],"Drug Drug Interaction",[1295,1312,1313,1314,1315,1316],"Tolbutamide","Metoprolol","Chlorzoxazone","Furosemide","Nitisinone in Arm B",{"trials":1318,"activeCount":91},[],{"trials":1320,"activeCount":91},[],{"trials":1322,"activeCount":91},[],{"trials":1324,"activeCount":91},[],{"intervention":1312,"totalTrials":101,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1328,"activeCount":91},[],{"trials":1330,"activeCount":91},[1331],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1332,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1333,"interventions":1334},[80],[1310],[1295,1312,1313,1314,1315,1316],{"trials":1336,"activeCount":91},[],{"trials":1338,"activeCount":91},[],{"trials":1340,"activeCount":91},[],{"trials":1342,"activeCount":91},[],{"intervention":1313,"totalTrials":101,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1346,"activeCount":91},[],{"trials":1348,"activeCount":91},[1349],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1350,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1351,"interventions":1352},[80],[1310],[1295,1312,1313,1314,1315,1316],{"trials":1354,"activeCount":91},[],{"trials":1356,"activeCount":91},[],{"trials":1358,"activeCount":91},[],{"trials":1360,"activeCount":91},[],{"intervention":1314,"totalTrials":101,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":91},[],{"trials":1366,"activeCount":91},[1367],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1368,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1369,"interventions":1370},[80],[1310],[1295,1312,1313,1314,1315,1316],{"trials":1372,"activeCount":91},[],{"trials":1374,"activeCount":91},[],{"trials":1376,"activeCount":91},[],{"trials":1378,"activeCount":91},[],{"intervention":1315,"totalTrials":101,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":91},[],{"trials":1384,"activeCount":91},[1385],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1386,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1387,"interventions":1388},[80],[1310],[1295,1312,1313,1314,1315,1316],{"trials":1390,"activeCount":91},[],{"trials":1392,"activeCount":91},[],{"trials":1394,"activeCount":91},[],{"trials":1396,"activeCount":91},[],{"intervention":1316,"totalTrials":101,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":91},[],{"trials":1402,"activeCount":91},[1403],{"nctId":1302,"briefTitle":1303,"status":206,"phases":1404,"primaryCompletion":1305,"completion":1306,"start":1307,"enrollment":1308,"conditions":1405,"interventions":1406},[80],[1310],[1295,1312,1313,1314,1315,1316],{"trials":1408,"activeCount":91},[],{"trials":1410,"activeCount":91},[],{"trials":1412,"activeCount":91},[],{"trials":1414,"activeCount":91},[],{"intervention":1416,"totalTrials":101,"cells":1417},"Nascobal nasal spray",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1419,"activeCount":91},[],{"trials":1421,"activeCount":91},[1422],{"nctId":1423,"briefTitle":1424,"status":206,"phases":1425,"primaryCompletion":446,"completion":446,"start":1426,"enrollment":186,"conditions":1427,"interventions":1429},"NCT01306123","Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration",[80],"2011-02",[1428],"Focus: Bioavailability",[1416,1430],"Vitamin B12-ratiopharm N, injection solution",{"trials":1432,"activeCount":91},[],{"trials":1434,"activeCount":91},[],{"trials":1436,"activeCount":91},[],{"trials":1438,"activeCount":91},[],{"intervention":1430,"totalTrials":101,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1442,"activeCount":91},[],{"trials":1444,"activeCount":91},[1445],{"nctId":1423,"briefTitle":1424,"status":206,"phases":1446,"primaryCompletion":446,"completion":446,"start":1426,"enrollment":186,"conditions":1447,"interventions":1448},[80],[1428],[1416,1430],{"trials":1450,"activeCount":91},[],{"trials":1452,"activeCount":91},[],{"trials":1454,"activeCount":91},[],{"trials":1456,"activeCount":91},[],{"intervention":1458,"totalTrials":18,"cells":1459},"Nitisinone",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1472,"PHASE3":1474,"PHASE4":1484,"NA":1486},{"trials":1461,"activeCount":91},[],{"trials":1463,"activeCount":91},[1464],{"nctId":1465,"briefTitle":1466,"status":206,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":229,"enrollment":1469,"conditions":1470,"interventions":1471},"NCT01734889","Taste and Palatability of Orfadin Suspension",[80],"2013-03",18,[20],[1458],{"trials":1473,"activeCount":91},[],{"trials":1475,"activeCount":91},[1476],{"nctId":1477,"briefTitle":1478,"status":206,"phases":1479,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":1469,"conditions":1482,"interventions":1483},"NCT02323529","Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1",[82],"2015-09","2014-12",[20],[1458],{"trials":1485,"activeCount":91},[],{"trials":1487,"activeCount":91},[1488,1497],{"nctId":1489,"briefTitle":1490,"status":206,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1496},"NCT02320084","Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care",[],"2019-09-30","2013-09",315,[20],[1458],{"nctId":1498,"briefTitle":1499,"status":492,"phases":1500,"primaryCompletion":1501,"completion":1501,"start":1502,"enrollment":91,"conditions":1503,"interventions":1504},"NCT06227429","A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients",[],"2027-06-30","2025-09",[20],[1458],{"intervention":1506,"totalTrials":25,"cells":1507},"Alprolix",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1509,"activeCount":91},[],{"trials":1511,"activeCount":91},[],{"trials":1513,"activeCount":91},[],{"trials":1515,"activeCount":91},[],{"trials":1517,"activeCount":91},[],{"trials":1519,"activeCount":91},[1520,1529,1533],{"nctId":1521,"briefTitle":1522,"status":206,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1528},"NCT03655340","A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France",[],"2022-03-16","2018-09-12",91,[22],[1506],{"nctId":348,"briefTitle":349,"status":206,"phases":1530,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":1531,"interventions":1532},[],[355,22],[51,357],{"nctId":1534,"briefTitle":1535,"status":206,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":208,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT03901755","An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B",[],"2024-03-12",151,[1540],"Hemophilia B",[1506],{"intervention":1543,"totalTrials":101,"cells":1544},"efmoroctocog alfa",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1546,"activeCount":91},[],{"trials":1548,"activeCount":91},[],{"trials":1550,"activeCount":91},[],{"trials":1552,"activeCount":91},[],{"trials":1554,"activeCount":91},[],{"trials":1556,"activeCount":91},[1557],{"nctId":1558,"briefTitle":1559,"status":206,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":954,"enrollment":1562,"conditions":1563,"interventions":1564},"NCT02976753","Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products",[],"2021-11-03",361,[14],[1543,1565],"Factor VIII",{"intervention":1565,"totalTrials":101,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1569,"activeCount":91},[],{"trials":1571,"activeCount":91},[],{"trials":1573,"activeCount":91},[],{"trials":1575,"activeCount":91},[],{"trials":1577,"activeCount":91},[],{"trials":1579,"activeCount":91},[1580],{"nctId":1558,"briefTitle":1559,"status":206,"phases":1581,"primaryCompletion":1561,"completion":1561,"start":954,"enrollment":1562,"conditions":1582,"interventions":1583},[],[14],[1543,1565],{"intervention":1585,"totalTrials":101,"cells":1586},"Avatrombopag",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1588,"activeCount":91},[],{"trials":1590,"activeCount":91},[],{"trials":1592,"activeCount":91},[],{"trials":1594,"activeCount":91},[],{"trials":1596,"activeCount":91},[],{"trials":1598,"activeCount":91},[1599],{"nctId":1600,"briefTitle":1601,"status":206,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1609},"NCT04943042","An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP",[],"2025-06-10","2022-02-22",199,[1607,1608],"Immune Thrombocytopenia","ITP",[1585]]